Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Simsek, Eda; Eskazan, Ahmet; Cengiz, Mahir; AR, MUHLİS; Ekizoglu, Seda; Salihoglu, Ayse; Gulturk, Emine; ELVERDİ, TUĞRUL; Aydin, Seniz; DEMİRÖZ, AHU; Buyru, Ayse; Baslar, Zafer; ÖZBEK, UĞUR; Ferhanoglu, Burhan; Aydin, Yildiz; Tuzuner, Nukhet; Soysal, Teoman

doi:10.1136/jclinpath-2015-203320

Imatinib reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukaemia

Copy For Citation

Simsek E. T., Eskazan A. E., Cengiz M., AR M. C., Ekizoglu S., Salihoglu A., ...More

JOURNAL OF CLINICAL PATHOLOGY, vol.69, no.9, pp.810-816, 2016 (SCI-Expanded)

Publication Type: Article / Article
Volume: 69 Issue: 9
Publication Date: 2016
Doi Number: 10.1136/jclinpath-2015-203320
Journal Name: JOURNAL OF CLINICAL PATHOLOGY
Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Page Numbers: pp.810-816
Keywords: CML, MYELOFIBROS, HEMATOPATHOLOGY, CHRONIC MYELOGENOUS LEUKEMIA, KINASE INHIBITOR STI571, CHRONIC-PHASE, RELEVANCE, THERAPY, RECOMMENDATIONS, DIAGNOSIS
Acibadem Mehmet Ali Aydinlar University Affiliated: Yes

Abstract

Aims Before the era of tyrosine kinase inhibitors (TKIs), the presence of bone marrow fibrosis (MF) in patients with chronic myeloid leukaemia (CML) has been established as a poor prognostic factor. The aim of the present study was to evaluate the effects of imatinib treatment on MF and the prognostic significance of MF at this new era of CML therapy.